PARIS, Feb 26 (Reuters) - Sanofi-Aventis (SASY.PA) has won U.S. approval to market its Apidra Solostar injection pen which contains insulin to treat diabetes, the world’s third-biggest drugmaker said on Thursday.
The disposable pen is prefilled with Apidra, which is indicated to improve glycemic control in adults and children of at least four years with type 1 diabetes or adults with type 2 diabetes, the most common form of the disease.
Separately, Sanofi’s vaccine division Sanofi Pasteur gained European Union marketing go-ahead for flu vaccine Intanza, also known as IDflu.
This vaccine is the first that can be injected into the dermal layer of the skin due to its very fine needle, Sanofi said. The vaccine’s needle is 10 times smaller than standard needles used for the traditional intramuscular route.
The vaccine is approved for the prevention of seasonal influenza in adults.